RORγT 是一种转录因子，可指导 Th17 淋巴细胞和其他表达 IL-17 的细胞（例如 Tc17 和 ILC3 细胞）的发育。这些细胞参与人体对病原细菌和真菌的防御，但它们也参与维持某些自身免疫性疾病中的促炎环境，并在免疫系统对癌症的反应中发挥作用。与核受体超家族的其他成员类似，RORγT 的活性受到低分子量配体的调节。因此，人们致力于鉴定反向激动剂，以减少该受体的活性并随后抑制自身免疫性疾病的发展。不幸的是，在追求理想的反向激动剂的过程中，激动剂的开发被忽视了。重要的是要记住，这些类型的化合物通过刺激表达 RORγT（Th17 和 Tc17）的淋巴细胞，可以增强免疫系统对肿瘤的反应。在这篇综述中，我们介绍了 RORγT 激动剂生物学的最新进展及其在抗癌治疗中的潜在应用。版权所有 © 2023 作者。由 Elsevier B.V. 出版。保留所有权利。

RORγT is a transcription factor that directs the development of Th17 lymphocytes and other IL-17-expressing cells (e.g., Tc17 and ILC3 cells). These cells are involved in the body's defense against pathogenic bacteria and fungi, but they also participate in maintaining the proinflammatory environment in some autoimmune diseases and play a role in the immune system's response to cancer. Similar to other members of the nuclear receptor superfamily, the activity of RORγT is regulated by low-molecular-weight ligands. Therefore, extensive efforts have been dedicated to identifying inverse agonists that diminish the activity of this receptor and subsequently inhibit the development of autoimmune diseases. Unfortunately, in the pursuit of an ideal inverse agonist, the development of agonists has been overlooked. It is important to remember that these types of compounds, by stimulating lymphocytes expressing RORγT (Th17 and Tc17), can enhance the immune system's response to tumors. In this review, we present recent advancements in the biology of RORγT agonists and their potential application in anticancer therapy.Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.